AlphaQuest LLC Has $886,000 Holdings in Amneal Pharmaceuticals, Inc. $AMRX

AlphaQuest LLC grew its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 78.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,561 shares of the company’s stock after buying an additional 38,858 shares during the quarter. AlphaQuest LLC’s holdings in Amneal Pharmaceuticals were worth $886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of AMRX. AustralianSuper Pty Ltd acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth about $3,238,000. Truist Financial Corp acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $137,000. Wealth Enhancement Advisory Services LLC increased its position in Amneal Pharmaceuticals by 31.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 17,574 shares of the company’s stock worth $182,000 after acquiring an additional 4,204 shares during the period. Concurrent Investment Advisors LLC acquired a new position in Amneal Pharmaceuticals during the 3rd quarter valued at $347,000. Finally, State of Alaska Department of Revenue bought a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at $170,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Activity

In related news, Director Ted C. Nark sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the sale, the director directly owned 291,029 shares in the company, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 231,856 shares of company stock valued at $2,743,724 in the last ninety days. 17.45% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Barclays started coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price for the company. Piper Sandler reiterated an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.80.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $14.19 on Tuesday. The firm has a 50-day moving average of $12.86 and a 200-day moving average of $10.91. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $15.00. The company has a market cap of $4.46 billion, a price-to-earnings ratio of 709.85 and a beta of 1.36.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.